IgG Fc engineering to modulate antibody effector functions

Fcγ receptors as regulators of immune responses

Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · see citing works

FcRn: the neonatal Fc receptor comes of age

Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · see citing works

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Cartron, G., Dacheux, L., Salles, G., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,902 · see citing works

Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity

Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · see citing works

The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity

Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · see citing works

The therapeutic monoclonal antibody market

Ecker, D. M., Jones, S. D., & Levine, H. L. (2014) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,292 · see citing works

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR

Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,164 · see citing works

Potent antibody therapeutics by design

Carter, P. J. (2006) · Nature reviews. Immunology · doi:10.1038/nri1837 · Cited by 1,103 · see citing works

THE COVALENT STRUCTURE OF AN ENTIRE γG IMMUNOGLOBULIN MOLECULE

Edelman, G. M., Cunningham, B. A., Gall, W. E., Gottlieb, P. D., Rutishauser, U. S., & Waxdal, M. J. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.63.1.78 · Cited by 903 · see citing works

Engineered antibody Fc variants with enhanced effector function

Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C. S. C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 805 · see citing works

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

Diebolder, C. A., Beurskens, F. J. M., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 797 · see citing works

Discovery and Development of the Complement Inhibitor Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · see citing works

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770 · see citing works

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · see citing works

The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex

Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719 · see citing works

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

Junghans, R. P., & Anderson, C. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5512 · Cited by 685 · see citing works

Enhanced antibody half-life improves in vivo activity

Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 657 · see citing works

Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)

Dall’Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 648 · see citing works

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20

Teeling, J. L., Mackus, W. J. M., Wiegman, L., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S. B., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609 · see citing works

Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Tao, M., & Morrison, S. L. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2595 · Cited by 531 · see citing works

Metabolic properties of IgG subclasses in man

Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 530 · see citing works

Impact of FcγRIIa-FcγRIIIa Polymorphisms and <i>KRAS</i> Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521 · see citing works

Disulfide bond structures of IgG molecules

Liu, H., & May, K. M. L. (2012) · mAbs · doi:10.4161/mabs.4.1.18347 · Cited by 487 · see citing works

Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice

Ghetie, V. F., Hubbard, J. G., Kim, J., Tsen, M. F., Lee, Y., & Ward, E. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260327 · Cited by 469 · see citing works

THE TRANSMISSION OF IMMUNITY FROM MOTHER TO YOUNG AND THE CATABOLISM OF IMMUNOGLOBULINS

Brambell, F. W. R. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92190-8 · Cited by 463 · see citing works

A Theoretical Model of γ-Globulin Catabolism

Brambell, F. W. R., Hemmings, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 451 · see citing works

Crystal structure of the complex of rat neonatal Fc receptor with Fc

Burmeister, W. P., Huber, A. H., & Björkman, P. J. (1994) · Nature · doi:10.1038/372379a0 · Cited by 432 · see citing works

Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

Idusogie, E. E., Presta, L. G., Gazzano, H., Tótpál, K., Wong, P. Y., Ultsch, M. H., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424 · see citing works

Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex

Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391 · see citing works

CD3-specific antibodies: a portal to the treatment of autoimmunity

Chatenoud, L., & Bluestone, J. A. (2007) · Nature reviews. Immunology · doi:10.1038/nri2134 · Cited by 389 · see citing works

Crystal structure of the complex of rat neonatal Fc receptor with Fc

(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90005-5 · Cited by 382 · see citing works

Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences

Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S., Patel, N., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368 · see citing works

The Immunoglobulin FactsBook

Lefranc, M., & Lefranc, M. (2001) · Cited by 367 · see citing works

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366 · see citing works

The Structure of a Human Type III Fcγ Receptor in Complex with Fc*

Radaev, S., Motyka, S., Fridman, W., Sautès-Fridman, C., & Sun, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100350200 · Cited by 362 · see citing works

Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor

Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L., & Björkman, P. J. (1994) · Nature · doi:10.1038/372336a0 · Cited by 336 · see citing works

Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn

Israel, E. J., Wilsker, D. F., Hayes, K. C., Schoenfeld, D., & Simister, N. E. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-775.x · Cited by 334 · see citing works

Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells

Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 314 · see citing works

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 312 · see citing works

Engineered Antibodies with Increased Activity to Recruit Complement

Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano, H., Tótpál, K., Ultsch, M. H., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291 · see citing works

Localization of the binding site for the human high-affinity Fc receptor on IgG

Duncan, A., Woof, J. M., Partridge, L. J., Burton, D. R., & Winter, G. P. (1988) · Nature · doi:10.1038/332563a0 · Cited by 288 · see citing works

Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors

Stavenhagen, J. B., Gorlatov, S. N., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., & Koenig, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0696 · Cited by 287 · see citing works

Current progress in innovative engineered antibodies

Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 282 · see citing works

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

Moore, G. L., Chen, H., Karki, S., & Lazar, G. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11158 · Cited by 266 · see citing works

The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.

Canfield, S. M., & Morrison, S. L. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.6.1483 · Cited by 266 · see citing works

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259 · see citing works

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.

Tao, M., Smith, R. I., & Morrison, S. L. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.2.661 · Cited by 251 · see citing works

Molecular engineering and design of therapeutic antibodies

Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250 · see citing works

Antibodies to watch in 2017

Reichert, J. M. (2016) · mAbs · doi:10.1080/19420862.2016.1269580 · Cited by 244 · see citing works

In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies

Xu, D., Alegre, M., Varga, S. S., Rothermel, A. L., Collins, A., Pulito, V. L., Hanna, L. S., Dolan, K. P., Parren, P. W. H. I., Bluestone, J. A., et al. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1617 · Cited by 240 · see citing works

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Bang, Y., Giaccone, G., Im, S.-A., Oh, D., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S.-H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx002 · Cited by 227 · see citing works

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W. C., Bumbaca, D., Shen, B., Du, X., Saad, O. M., Bowles, K. H., Olsen, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2093 · Cited by 218 · see citing works

The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

Bolt, S. L., Routledge, E. G., LLOYD, I. S., Chatenoud, L., Pope, H., Gorman, S. D., Clark, M., & Waldmann, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230216 · Cited by 218 · see citing works

Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG

Lund, J., Winter, G., Jones, P., Pound, J. D., Tanaka, T., Walker, M. R., Artymiuk, P. J., Arata, Y., Burton, D. R., Jefferis, R., et al. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2657 · Cited by 212 · see citing works

Marketing approval of mogamulizumab

Beck, A., & Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.20996 · Cited by 211 · see citing works

Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FcγRI and/or FcγRII receptors

Walker, M. R., Lund, J., Thompson, K. M., & Jefferis, R. (1989) · Biochemical Journal · doi:10.1042/bj2590347 · Cited by 191 · see citing works

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 187 · see citing works

Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1

Medesan, C., Matesoi, D., Radu, C., Ghetie, V, & Ward, E. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2211 · Cited by 175 · see citing works

FACTORS CONTROLLING SERUM γ-GLOBULIN CONCENTRATION

Fahey, J. L., & ROBINSON, A. G. (1963) · The Journal of Experimental Medicine · doi:10.1084/jem.118.5.845 · Cited by 173 · see citing works

Inhibitory ITAMs as novel regulators of immunity

Blank, U., Launay, P., Benhamou, M., & Monteiro, R. C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00832.x · Cited by 168 · see citing works

Structural Basis for FcγRIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes

Ramsland, P. A., Farrugia, W., Bradford, T. M., Sardjono, C. T., Esparon, S. E., Trist, H. M., Powell, M. S., Tan, P. S., Cendron, A. C., Wines, B. D., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101467 · Cited by 164 · see citing works

The Immunologic Functions of the Neonatal Fc Receptor for IgG

Räth, T., Kuo, T. T., Baker, K., Qiao, S., Kobayashi, K., Yoshida, M., Roopenian, D. C., Fiebiger, E., Lencer, W. I., & Blumberg, R. S. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9768-y · Cited by 159 · see citing works

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

Chu, S. Y., Voštiar, I., Karki, S., Moore, G. L., Lazar, G. A., Pong, E., Joyce, P. F., Szymkowski, D. E., & Desjarlais, J. R. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.027 · Cited by 156 · see citing works

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

Vafa, O., Gilliland, G. L., Brezski, R. J., Strake, B., Wilkinson, T., Lacy, E. R., Scallon, B. J., Teplyakov, A., Malia, T., & Strohl, W. R. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.035 · Cited by 154 · see citing works

Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding

Lu, J., Chu, J., Zou, Z., Hamacher, N. B., Rixon, M. W., & Sun, P. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418812112 · Cited by 153 · see citing works

The IgG Fc Contains Distinct Fc Receptor (FcR) Binding Sites: The Leukocyte Receptors FcγRI and FcγRIIa Bind to a Region in the Fc Distinct from That Recognized by Neonatal FcR and Protein A

Wines, B. D., Powell, M. S., Parren, P. W. H. I., Barnes, N. C., & Hogarth, P. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5313 · Cited by 152 · see citing works

Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI

Kiyoshi, M., Caaveiro, J. M. M., Kawai, T., Tashiro, S., Ide, T., Asaoka, Y., Hatayama, K., & Tsumoto, K. (2015) · Nature Communications · doi:10.1038/ncomms7866 · Cited by 151 · see citing works

Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.

Chappel, M. S., Isenman, D. E., Everett, M., Xu, Y. Y., Dorrington, K. J., & Klein, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9036 · Cited by 131 · see citing works

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131

Mimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T., Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., & Hattori, K. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt022 · Cited by 127 · see citing works

Localisation of the monocyte-binding region on human immunoglobulin G

Woof, J. M., Partridge, L. J., Jefferis, R., & Burton, D. R. (1986) · Molecular Immunology · doi:10.1016/0161-5890(86)90059-3 · Cited by 120 · see citing works

Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody

Alegre, M. L. S., Collins, A., Pulito, V. L., Brosius, R., Olson, W. C., Zivin, R. A., Knowles, R. W., Thistlethwaite, J. R., Jolliffe, L. K., & Bluestone, J. A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.11.3461 · Cited by 116 · see citing works

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer

Gavin, P. G., Song, N., Kim, S. R., Lipchik, C., Johnson, N. L., Bandos, H., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4884 · Cited by 113 · see citing works

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

Leabman, M. K., Meng, Y. G., Kelley, R. F., DeForge, L. E., Cowan, K. J., & Iyer, S. (2013) · mAbs · doi:10.4161/mabs.26436 · Cited by 110 · see citing works

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

Meyer, S., Leusen, J. H. W., & Boross, P. (2014) · mAbs · doi:10.4161/mabs.29670 · Cited by 109 · see citing works

IgG2m4, an engineered antibody isotype with reduced Fc function

An, Z., Forrest, G., Moore, R., Cukan, M. C., Haytko, P., Huang, L., Vitelli, S., Zhao, J. Z., Lü, P., Hua, J., et al. (2009) · mAbs · doi:10.4161/mabs.1.6.10185 · Cited by 103 · see citing works

Structural characterization of a mutated, ADCC-enhanced human Fc fragment

Oganesyan, V., Damschroder, M. M., Leach, W., Wu, H., & Dall’Acqua, W. F. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.10.042 · Cited by 89 · see citing works

Immunoglobulin isotype knowledge and application to Fc engineering

Brezski, R. J., & Georgiou, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.002 · Cited by 82 · see citing works

Evidence of NI‐0101 pharmacological activity, an anti‐TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS

Monnet, E., Lapeyre, G., van Poelgeest, E. P., Jacqmin, P., de Graaf, K., Reijers, J. A. A., Moerland, M., Burggraaf, J., & de Min, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.522 · Cited by 79 · see citing works

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant

Mimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., Shida-Kawazoe, M., & Hattori, K. (2013) · mAbs · doi:10.4161/mabs.23452 · Cited by 74 · see citing works

Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation

Thommesen, J. E., Michaelsen, T. E., Løset, G. Å., Sandlie, I., & Brekke, O. H. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00010-4 · Cited by 71 · see citing works

Identification of the IgG binding site of the human low affinity receptor for IgG Fc gamma RII. Enhancement and ablation of binding by site-directed mutagenesis.

Hulett, M. D., Witort, E. J., Brinkworth, R. I., McKenzie, I. F. C., & Hogarth, P. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36604-8 · Cited by 66 · see citing works

Molecular definition of interaction sites on human IgG for Fc receptors (huFcγR)

Jefferis, R., Lund, J., & Pound, J. D. (1990) · Molecular Immunology · doi:10.1016/0161-5890(90)90027-w · Cited by 61 · see citing works

The IgG Binding Site of Human FcγRIIIB Receptor Involves CC′ and FG Loops of the Membrane-proximal Domain

Tamm, A., Kister, A. E., Nolte, K., Gessner, J. E., & Schmidt, R. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3659 · Cited by 60 · see citing works

Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1

Nesspor, T., Raju, T. S., Chin, C., Vafa, O., & Brezski, R. J. (2012) · Journal of Molecular Recognition · doi:10.1002/jmr.2155 · Cited by 52 · see citing works

Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19

Szili, D., Cserhalmi, M., Bankó, Z., Nagy, G., Szymkowski, D. E., & Sármay, G. (2014) · mAbs · doi:10.4161/mabs.28841 · Cited by 45 · see citing works

Selective Antibody Intervention of Toll-like Receptor 4 Activation through Fc γ Receptor Tethering

Shang, L., Daubeuf, B., Triantafilou, M., Olden, R., Dépis, F., Raby, A., Herren, S., Santos, A. D., Malinge, P., Dunn-Siegrist, I., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537936 · Cited by 39 · see citing works

Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI)

Burton, D. R., Jefferis, R., Partridge, L. J., & Woof, J. M. (1988) · Molecular Immunology · doi:10.1016/0161-5890(88)90153-8 · Cited by 36 · see citing works

The use of anti-IgG monoclonal antibodies in mapping the monocyte receptor site on IgG

PARTRIDGE, L., Woof, J. M., Jefferis, R., & Burton, D. R. (1986) · Molecular Immunology · doi:10.1016/0161-5890(86)90022-2 · Cited by 35 · see citing works

A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo

Brezski, R. J., Kinder, M., Grugan, K. D., Soring, K. L., Carton, J. M., Greenplate, A. R., Petley, T., Capaldi, D., Brosnan, K., Emmell, E., et al. (2014) · mAbs · doi:10.4161/mabs.29825 · Cited by 28 · see citing works

Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding

Oganesyan, V., Mazor, Y., Yang, C., Cook, K. E., Woods, R. M., Ferguson, A. D., Bowen, M. A., Martin, T., Zhu, J., Wu, H., et al. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715018015 · Cited by 26 · see citing works

Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies

Strohl, W. R. (2011) · Modecular medicine and medicinal · doi:10.1142/9781848166295_0005 · Cited by 13 · see citing works

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors

Loyau, J., Malinge, P., Daubeuf, B., Shang, L., Elson, G., Kosco‐Vilbois, M. H., Fischer, N., & Rousseau, F. (2014) · mAbs · doi:10.4161/19420862.2014.975098 · Cited by 8 · see citing works

Conditionally reprogrammed pancreatic cancer cells: A novel patient-derived cell line model for human pancreatic cancer studies

Bang, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx261.040 · Cited by 4 · see citing works

Untitled work

(1999) · doi:10.1002/(sici)1521-4141(199909)29:09

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · see citing works

Antibody Structure and Function: The Basis for Engineering Therapeutics

Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 646 · see citing works

Natural killer cell therapies

Vivier, É., Rebuffet, L., Narni-Mancinelli, É., Cornen, S., Igarashi, R., & Fantin, V. R. (2024) · Nature · doi:10.1038/s41586-023-06945-1 · Cited by 481 · see citing works

Emerging new therapeutic antibody derivatives for cancer treatment

Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 461 · see citing works

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life

Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 315 · see citing works

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

Kruse, R. L. (2020) · F1000Research · doi:10.12688/f1000research.22211.2 · Cited by 312 · see citing works

Considerations for the Design of Antibody-Based Therapeutics

Goulet, D. R., & Atkins, W. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 305 · see citing works

Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates

Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286 · see citing works

Cancer therapy with antibodies

Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00690-x · Cited by 271 · see citing works

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

Liu, R., Oldham, R. J., Teal, E. L., Beers, S. A., & Cragg, M. S. (2020) · Antibodies · doi:10.3390/antib9040064 · Cited by 243 · see citing works

Resistance to Antibody–Drug Conjugates

García‐Alonso, S., Ocaña, A., & Pandiella, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3671 · Cited by 213 · see citing works

New immune cell engagers for cancer immunotherapy

Fenis, A., Demaria, O., Gauthier, L., Vivier, É., & Narni-Mancinelli, É. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00982-7 · Cited by 212 · see citing works

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202 · see citing works

Mechanisms of Therapeutic Antitumor Monoclonal Antibodies

Tsao, L.-C., Force, J. M., & Hartman, Z. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1109 · Cited by 205 · see citing works

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

Pang, X., Huang, Z., Zhong, T., Zhang, P., Wang, Z. M., Xia, M., & Li, B. (2023) · mAbs · doi:10.1080/19420862.2023.2180794 · Cited by 198 · see citing works

Transferrin receptor targeting chimeras for membrane protein degradation

Zhang, D., Duque-Jimenez, J., Facchinetti, F., Brixi, G., Rhee, K., Feng, W. W., Janne, P. A., & Zhou, X. X. (2024) · Nature · doi:10.1038/s41586-024-07947-3 · Cited by 205 · see citing works

Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms

Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186 · see citing works

Bispecific and multispecific antibodies in oncology: opportunities and challenges

Goebeler, M.-E., Stuhler, G., & Bargou, R. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00905-y · Cited by 191 · see citing works

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

Shim, H. (2020) · Biomolecules · doi:10.3390/biom10030360 · Cited by 167 · see citing works

Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies

Martin-Alonso, C., Tabrizi, S., Xiong, K., Blewett, T., Sridhar, S., Crnjac, A., Patel, S., An, Z., Bekdemir, A., Shea, D., et al. (2024) · Science · doi:10.1126/science.adf2341 · Cited by 157 · see citing works

Boosting therapeutic potency of antibodies by taming Fc domain functions

Kang, T. H., & Jung, S. T. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0345-9 · Cited by 142 · see citing works

A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer’s disease

Zhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141 · see citing works

Role of Fcγ receptors in HER2-targeted breast cancer therapy

Musolino, A., Gradishar, W. J., Rugo, H. S., Nordstrom, J. L., Rock, E. P., Arnaldez, F. I., & Pegram, M. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003171 · Cited by 138 · see citing works

Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

Ben‐Shmuel, A., Biber, G., & Barda‐Saad, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00275 · Cited by 134 · see citing works

Ion channels as therapeutic antibody targets

Hutchings, C. J., Colussi, P. A., & Clark, T. G. (2018) · mAbs · doi:10.1080/19420862.2018.1548232 · Cited by 127 · see citing works

Impact of structural modifications of IgG antibodies on effector functions

Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 128 · see citing works

Fc-engineered antibodies with immune effector functions completely abolished

Wilkinson, I. C., Anderson, S., Fry, J. W., Julien, L. A., Neville, D. C. A., Qureshi, O. S., Watts, G., & Hale, G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260954 · Cited by 127 · see citing works

Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19

Saha, R. P., Sharma, A. R., Singh, M. K., Samanta, S., Bhakta, S., Mandal, S., Bhattacharya, M., Lee, S. S., & Chakraborty, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01258 · Cited by 116 · see citing works

Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma

Sun, L., Gao, F., Gao, Z., Ao, L., Li, N., Ma, S., Jia, M., Li, N., Lu, P., Sun, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001875 · Cited by 118 · see citing works

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

Husain, B., & Ellerman, D. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0299-9 · Cited by 116 · see citing works

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease

Ayalon, G., Lee, S.-H., Adolfsson, O., Foo‐Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H. S., Bravo, J., Brendza, R. P., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 108 · see citing works

An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity

Ji, Y., Gao, Q., Ma, Y., Wang, F., Tan, X., Song, D., Hoo, R. L. C., Wang, Z., Ge, X., Han, H., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106720 · Cited by 111 · see citing works

Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study

Antozzi, C. G., Vu, T., Ramchandren, S., Nowak, R. J., Farmakidis, C., Bril, V., Bleecker, J. D., Yang, H., Minks, E., Park, J., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00498-8 · Cited by 104 · see citing works

Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation

Sifniotis, V., Cruz, E., Eroglu, B., & Kayser, V. (2019) · Antibodies · doi:10.3390/antib8020036 · Cited by 99 · see citing works

Sialylation as an Important Regulator of Antibody Function

Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 97 · see citing works

Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations

Gauzy, L., Sassoon, I., & Brun, M. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220912955 · Cited by 87 · see citing works

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

Pinto, D., Park, Y., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., Marco, A. D., et al. (2020) · Worldwide Protein Data Bank · doi:10.2210/pdb6ws6/pdb · Cited by 82 · see citing works

Immunoglobulins or Antibodies: IMGT® Bridging Genes, Structures and Functions

Lefranc, M., & Lefranc, G. (2020) · Biomedicines · doi:10.3390/biomedicines8090319 · Cited by 83 · see citing works

Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations

Delidakis, G., Kim, J. E., George, K., & Georgiou, G. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082721-024500 · Cited by 84 · see citing works

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers

Pinto, S., Pahl, J. H. W., Schottelius, A. J. G., Carter, P. J., & Koch, J. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.09.007 · Cited by 78 · see citing works

Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies

Chu, T. H., Crowley, A. R., Backes, I. M., Chang, C. H., Tay, M. Z., Broge, T. A., Tuyishime, M., Ferrari, G., Seaman, M. S., Richardson, S. I., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008083 · Cited by 80 · see citing works

Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs

Capuano, C., Pighi, C., Battella, S., Federicis, D. D., Galandrini, R., & Palmieri, G. (2021) · Cancers · doi:10.3390/cancers13102500 · Cited by 78 · see citing works

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer

Rassy, E., Rached, L., & Pistilli, B. (2022) · The Breast · doi:10.1016/j.breast.2022.10.016 · Cited by 77 · see citing works

Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development

Wang, Y., Zhang, X., Wang, Y., Zhao, W., Li, H., Zhang, L., Li, X., Zhang, T., Zhang, H., Huang, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.004 · Cited by 76 · see citing works

Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow

Ahamadi-Fesharaki, R., Fateh, A., Vaziri, F., Solgi, G., Siadat, S. D., Mahboudi, F., & Jamnani, F. R. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.02.004 · Cited by 76 · see citing works

Complement C4 Prevents Viral Infection through Capsid Inactivation

Bottermann, M., Foss, S., Caddy, S., Clift, D., van Tienen, L. M., Vaysburd, M., Cruickshank, J., O’Connell, K., Clark, J., Mayes, K., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.02.016 · Cited by 75 · see citing works

Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies

Aoyama, M., Hashii, N., Tsukimura, W., Osumi, K., Harazono, A., Tada, M., Kiyoshi, M., Matsuda, A., & Ishii‐Watabe, A. (2019) · mAbs · doi:10.1080/19420862.2019.1608143 · Cited by 73 · see citing works

Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell–Mediated Antibody-Dependent Cellular Cytotoxicity

Temming, A. R., de Taeye, S. W., de Graaf, E. L., de Neef, L. A., Dekkers, G., Bruggeman, C. W., Koers, J., Ligthart, P. C., Nagelkerke, S. Q., Zimring, J. C., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900985 · Cited by 72 · see citing works

Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo

Wang, P., Gajjar, M. R., Yu, J., Padte, N. N., Gettie, A., Blanchard, J., Russell‐Lodrigue, K., Liao, L. E., Perelson, A. S., Huang, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008190117 · Cited by 71 · see citing works

Engineering antibody and protein therapeutics to cross the blood–brain barrier

Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 71 · see citing works

Silencing Fc Domains in T cell–Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency

Wang, L., Hoseini, S. S., Xu, H., Ponomarev, V., & Cheung, N. V. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0121 · Cited by 69 · see citing works

Advances and challenges in therapeutic monoclonal antibodies drug development

dos Santos, M. L., Quintilio, W., Manieri, T. M., Tsuruta, L. R., & Moro, A. M. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902018000001007 · Cited by 68 · see citing works

A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

Boustany, L. M., LaPorte, S. L., Wong, L., White, C. W., Vinod, V., Shen, J., Yu, W., Koditek, D., Winter, M. B., Moore, S. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2483 · Cited by 67 · see citing works

Anti–PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases

Suzuki, K., Tajima, M., Tokumaru, Y., Oshiro, Y., Nagata, S., Kamada, H., Kihara, M., Nakano, K., Honjo, T., & Ohta, A. (2023) · Science Immunology · doi:10.1126/sciimmunol.add4947 · Cited by 64 · see citing works

Blueprint for antibody biologics developability

Mieczkowski, C., Zhang, X., Lee, D., Nguyen, K., Lv, W., Wang, Y., Zhang, Y., Way, J., & Gries, J. (2023) · mAbs · doi:10.1080/19420862.2023.2185924 · Cited by 65 · see citing works

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 66 · see citing works

Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs

Groof, T. W. M. D., Bobkov, V., Heukers, R., & Smit, M. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.01.021 · Cited by 62 · see citing works

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

Oostindie, S. C., van der Horst, H. J., Lindorfer, M. A., Cook, E. M., Tupitza, J. C., Zent, C. S., Burack, R., VanDerMeid, K. R., Strumane, K., Chamuleau, M. E. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.207266 · Cited by 61 · see citing works

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Peluso, M. O., Adam, A., Armet, C. M., Zhang, L., O’Connor, R. W., Lee, B. H., Lake, A. C., Normant, E., Chappel, S. C., Hill, J. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000413 · Cited by 61 · see citing works

Impact of IgG subclass on molecular properties of monoclonal antibodies

Tang, Y., Cain, P., Anguiano, V., Shih, J., Chai, Q., & Feng, Y. (2021) · mAbs · doi:10.1080/19420862.2021.1993768 · Cited by 59 · see citing works

Next generation of multispecific antibody engineering

Kéri, D., Walker, M., Singh, I., Nishikawa, K. K., & Garcés, F. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad027 · Cited by 57 · see citing works

Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A cross‐over, randomized, double‐blind, controlled inpatient physiology study

Tuccinardi, D., Farr, O. M., Upadhyay, J., Oussaada, S. M., Klapa, M. I., Candela, M., Rampelli, S., Lehoux, S. D., Lázaro, I., Sala‐Vila, A., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13773 · Cited by 57 · see citing works

Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies

Briani, C., & Visentin, A. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01222-x · Cited by 56 · see citing works

A toolbox of IgG subclass-switched recombinant monoclonal antibodies for enhanced multiplex immunolabeling of brain

Andrews, N. P., Boeckman, J. X., Manning, C. F., Nguyen, J. T., Bechtold, H., Dumitras, C., Gong, B., Nguyen, K., van der List, D. A., Murray, K. D., et al. (2019) · eLife · doi:10.7554/elife.43322 · Cited by 52 · see citing works

The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras

Kelley, B. D. (2024) · mAbs · doi:10.1080/19420862.2024.2373330 · Cited by 53 · see citing works

Logic-gated antibody pairs that selectively act on cells co-expressing two antigens

Oostindie, S. C., Rinaldi, D. A., Zom, G. G., Wester, M. J., Paulet, D., Al-Tamimi, K., van der Meijden, E., Scheick, J. R., Wilpshaar, T. A., de Jong, B., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01384-1 · Cited by 51 · see citing works

Functional selection of protease inhibitory antibodies

Lopez, T., Mustafa, Z., Chen, C., Lee, K. B., Ramirez, A., Benitez, C., Luo, X., Ji, R., & Ge, X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903330116 · Cited by 50 · see citing works

Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation

Rashid, M. H. (2022) · mAbs · doi:10.1080/19420862.2022.2111748 · Cited by 47 · see citing works

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

VanDyke, D., Iglesias, M., Tomala, J., Young, A., Smith, J., Perry, J. A., Gebara, E., Cross, A. R., Cheung, L. S., Dykema, A. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111478 · Cited by 47 · see citing works

CD22 Blockage Restores Age-Related Impairments of Microglia Surveillance Capacity

Aires, V., Coulon-Bainier, C., Pavlovic, A., Ebeling, M., Schmucki, R., Schweitzer, C., Kueng, E., Gutbier, S., & Harde, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684430 · Cited by 46 · see citing works

Tolerance mechanisms of allergen immunotherapy

van de Veen, W., & Akdiş, M. (2019) · Allergy · doi:10.1111/all.14126 · Cited by 46 · see citing works

Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis

Fang, Q., Ou, J., & Nandakumar, K. S. (2019) · Mediators of Inflammation · doi:10.1155/2019/6363086 · Cited by 45 · see citing works

Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy

Hong, H., Han, L., Li, D., Gong, L., Zhou, K., Li, Y., Yu, H., Zhao, K., Shi, J., Zhou, Z., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202208773 · Cited by 44 · see citing works

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice

Zhao, P., Xu, Y., Fan, X., Li, L., Li, X., Arase, H., Tong, Q., Zhang, N., & An, Z. (2022) · mAbs · doi:10.1080/19420862.2022.2107971 · Cited by 45 · see citing works

Cutting-edge approaches to B-cell depletion in autoimmune diseases

Robinson, W. H., Fiorentino, D. F., Chung, L. S., Moreland, L. W., Deodhar, M., Harler, M., Saulsbery, C., & Kunder, R. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454747 · Cited by 45 · see citing works

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

Li, M., Zhao, R., Chen, J., Tian, W., Xia, C., Liu, X., Li, Y., Yan, Y., Li, S., Sun, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85329-9 · Cited by 43 · see citing works

The potential of engineered antibodies for HIV-1 therapy and cure

Grobben, M., Stuart, R. A., & van Gils, M. J. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.07.007 · Cited by 41 · see citing works

Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus

Vlahava, V.-M., Murrell, I., Zhuang, L., Aicheler, R., Lim, E. Y., Miners, K. L., Ladell, K., Suárez, N. M., Price, D. A., Davison, A. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139296 · Cited by 42 · see citing works

Modulating antibody effector functions by Fc glycoengineering

García-Alija, M., Moer, B. V., Sastre, D. E., Azzam, T., Du, J. J., Trastoy, B., Callewaert, N., Sundberg, E. J., & Guerin, M. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108201 · Cited by 41 · see citing works

Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects

Zhong, T., Zhang, L., Huang, Z., Pang, X., Jin, C., Liu, W., Du, J., Yin, W., Chen, N., Min, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111722 · Cited by 40 · see citing works

Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus

Jin, J., & Simmons, G. (2019) · Viruses · doi:10.3390/v11040305 · Cited by 40 · see citing works

Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies

Tajiri, M., Hashii, N., & Ishii‐Watabe, A. (2020) · Bioengineered · doi:10.1080/21655979.2020.1814683 · Cited by 39 · see citing works

Impact of N-Linked Glycosylation on Therapeutic Proteins

Chen, B., Liu, W., Li, Y., Ma, B., Shang, S., & Tan, Z. (2022) · Molecules · doi:10.3390/molecules27248859 · Cited by 39 · see citing works

Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies

Brennan, F. R., Polli, J. R., Sathish, J. G., Ramones, M., Wolf, B., Schlothauer, T., Peters, S. J., Maier, C. C., Ji, C., Wensel, D. L., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2505092 · Cited by 40 · see citing works

Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names

Wilkinson, I. C., & Hale, G. (2022) · mAbs · doi:10.1080/19420862.2022.2123299 · Cited by 38 · see citing works

Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors

Gu, Y., & Zhao, Q. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00734-w · Cited by 38 · see citing works

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN

Reis, E. S., Buonpane, R. A., Celik, H., Marty, C., Lei, A., Jobe, F., Rupar, M. J., Zhang, Y., DiMatteo, D., Awdew, R., et al. (2024) · Blood · doi:10.1182/blood.2024024373 · Cited by 40 · see citing works

Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives

Mayrhofer, P., & Kunert, R. (2018) · Human Antibodies · doi:10.3233/hab-180347 · Cited by 37 · see citing works

Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors

Hale, G., Vos, J. D., Davy, A. D., Sandra, K., & Wilkinson, I. (2024) · mAbs · doi:10.1080/19420862.2024.2402701 · Cited by 36 · see citing works

Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes

de Jong, R. M., Meerstein‐Kessel, L., Da, D. F., Nsango, S. E., Challenger, J. D., van de Vegte‐Bolmer, M., van Gemert, G., Duarte, E. M., Teyssier, N., Sauerwein, R. W., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00366-9 · Cited by 36 · see citing works

Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies

Zhao, H., Wang, H., Zhou, Q., & Ren, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0029 · Cited by 35 · see citing works

Antibody recognition of bacterial surfaces and extracellular polysaccharides

Soliman, C., Pier, G. B., & Ramsland, P. A. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.12.001 · Cited by 34 · see citing works

Effect of UVC Irradiation on the Oxidation of Histidine in Monoclonal Antibodies

Miyahara, Y., Shintani, K., Hayashihara, K., Zukawa, T., Morita, Y., Nakazawa, T., Yoshida, T., Ohkubo, T., & Uchiyama, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-63078-5 · Cited by 34 · see citing works

Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models

Valente, D., Mauriac, C., Schmidt, T., Focken, I., Beninga, J., Mackness, B. C., Qiu, H., Vicat, P., Kandira, A., Radošević, K., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1829337 · Cited by 34 · see citing works

Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species

Glover, Z. K., Wecksler, A. T., Aryal, B., Mehta, S. C., Pegues, M. A., Chan, W., Lehtimaki, M., Luo, A., Sreedhara, A., & Rao, V. A. (2022) · mAbs · doi:10.1080/19420862.2022.2122957 · Cited by 33 · see citing works

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

Frey, G., Cugnetti, A. P. G., Liu, H., Xing, C., Wheeler, C. E., Chang, H. W., Boyle, W. J., & Short, J. M. (2024) · mAbs · doi:10.1080/19420862.2024.2322562 · Cited by 33 · see citing works

Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells

Karampatzakis, A., Brož, P., Rey, C., Önfelt, B., Matos, G. D. S. C. D., Rycroft, D., Ambrose, A. R., & Davis, D. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641521 · Cited by 32 · see citing works

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

Lucas, A. T., Robinson, R., Schorzman, A. N., Piscitelli, J. A., Razo, J. F., & Zamboni, W. C. (2019) · Antibodies · doi:10.3390/antib8010003 · Cited by 31 · see citing works

Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region

Handlogten, M. W., Peng, L., Christian, E. A., Xu, W., Lin, S., Venkat, R. V., Dall’Acqua, W. F., & Ahuja, S. (2020) · mAbs · doi:10.1080/19420862.2020.1779974 · Cited by 31 · see citing works

Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors

Whalen, K. A., Rakhra, K., Mehta, N. K., Steinle, A., Michaelson, J. S., & Baeuerle, P. A. (2023) · mAbs · doi:10.1080/19420862.2023.2208697 · Cited by 31 · see citing works

Editorial: Effector functions of therapeutic antibodies

Boross, P., Peipp, M., & Nimmerjahn, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1126966 · Cited by 1 · see citing works

Fc Engineering: Design, Expression, and Functional Characterization of Antibody Variants with Improved Effector Function

Derer, S., Kellner, C., Berger, S., Valerius, T., & Peipp, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-974-7_30 · Cited by 21 · see citing works

Molecular engineering and design of therapeutic antibodies

Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250 · see citing works

Immunoglobulin isotype knowledge and application to Fc engineering

Brezski, R. J., & Georgiou, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.002 · Cited by 82 · see citing works

Novel Generation of Antibody-Based Therapeutics

Brezski, R. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00006-7 · Cited by 1 · see citing works